Introduction
Statins are generally prescribed as cholesterol-lowering agents for patients with cardiovascular disease and hypercholesterolemia. Statins act by reducing de novo cholesterol synthesis through the inhibition of 3-hydroxy-3-metylglutaryl coenzyme A reductase (HMGCR), the rate-limiting enzyme of the mevalonate pathway (1) . Further, HMGCR has been suggested to harbor oncogenic potential, and deregulation of the mevalonate pathway may promote transformation (2) . A growing amount of literature has addressed the cholesterol-independent pleiotropic effects exerted by statins, including favorable anti-cancer effects (3) (4) (5) (6) . In vitro studies using lipophilic statins have shown reduced tumor cell proliferation, invasiveness, and survival following statin treatment (3, 4, 7) . In vivo studies have confirmed statin-induced tumor growth inhibition associated with reduced tumor cell proliferation and survival (3) . A previous phase II statin trial conducted by Garwood et al. showed significant changes in high-grade breast cancer tumors, including reduced proliferation and increased apoptosis (5) . The complexity of the anti-cancer properties of statins also includes cholesterol-dependent effects driven by the systemic lowering of cholesterol levels, thus depriving tumor cells from their increased demand of cholesterol uptake (8) .
Previous statin breast cancer trials have reported changes in single genes or proteins, but statin-mediated changes in cancer-specific whole genome expression profiles have not been reported. Gene expression profiling has predominantly been used to classify tumors, to identify biological signatures and to search for novel biomarkers (9, 10) . The comparison of gene expression profiles in tumor biopsies acquired before and after a given treatment enables identification of important signaling pathways and may detect transcriptional responses to a specific therapy. Author Manuscript Published OnlineFirst on April 3, 2015; DOI: 10.1158/1078-0432.CCR- We have previously reported changes in the protein expression of Ki67 and HMGCR in tumors from breast cancer patients treated with high-dose statins for two weeks prior to surgery within this phase II window-of-opportunity trial (11) . In this part of the trial, the aim was to investigate statin-induced effects at the transcriptional level by comparing pretreatment and post-treatment samples in order to deepen the insight into the molecular mechanisms of statins in breast cancer.
Materials and Methods

Trial design
The trial was designed as a phase II study using the "window-of-opportunity" design, in which the treatment-free window between a cancer diagnosis and surgical tumor resection is used to study the biological effects of a certain drug. In this trial, atorvastatin, a lipophilic statin, was prescribed to patients with primary breast cancer for two weeks pre-operatively.
As a non-randomized trial, all patients received an equal daily dose of 80 mg of atorvastatin for two weeks. The trial was conducted as a single-center study at Skåne University Hospital in Lund, Sweden. All patients signed an informed consent form. The Ethics Committee at Lund University and the Swedish Medical Products Agency approved this trial. The study has been registered at ClinicalTrials.gov (NCT00816244) and adheres to the REMARK guidelines (12) .
Patients
Patients were included according to the trial's inclusion criteria, which have been reported in detail earlier (11) total of 42 patients completed all parts of the study. The motivations for discontinuation have been reported previously (11) .
Endpoints and tumor evaluation
The primary endpoint of the study was statin-induced tumor response measured as change in tumor proliferation (i.e. Ki67 protein expression). The secondary endpoints included change in tumoral HMGCR expression as well as changes in gene expression following pre-surgical atorvastatin during a two-week "window-of-opportunity" period. At the time of enrollment, all participants underwent study specific core biopsies prior to the initiation of statin treatment. From each patient, one core biopsy was formalin-fixed immediately, and another core was collected and stored at -80°C. Following the two-week statin treatment, breast surgery was performed according to standard surgical procedures, and both fresh frozen and formalin-fixed tumor tissue was retrieved from the primary tumor at the Department of Pathology at Skåne University Hospital, Lund, Sweden.
Cell lines, cell culture and treatments
The human breast cancer cell lines MCF7, BT474, SKBR3 and MDAMB231 were purchased from the American Type Culture Collection (Rockville, MD) and maintained in culture as recommended by the vendors. Atorvastatin was purchased from Sigma and diluted in dimethyl sulphoxide (DMSO). Cells were exposed to either atorvastatin or vehicle (DMSO) for 48 hours after which total RNA was extracted and subjected to whole genome transcriptional profiling. Three independent experiments were performed per cell line.
RNA extraction
Total RNA was extracted from fresh frozen tumor samples and cell lines using an Allprep in two batches at the SCIBLU Genomics Center at Lund University, Sweden (www.lu.se/sciblu). RNA extracted from cell lines was processed in one batch at a later time point. The Illumina probes were re-annotated using the R package illuminaHumanv4.db (13) .
The gene expression data have been submitted to the NCBI's Gene Expression Omnibus (GEO) database (GSE63427).
Microarray data analysis and statistical analysis
Microarray data were initially pre-processed and normalized using the Quantile Normalization method (14) . These analyses were performed using GenomeStudio Software V2011.1. Probe sets with signal intensities below the median of the negative control intensity signals in ≥80% of the samples were excluded. Replicate probe sets were merged by the median of signal intensity values. A principal component analysis (PCA) investigating associations between technical factors with the main principal components was performed whereupon a batch effect was detected to be associated with the 7 th PC. A supervised empirical Bayes method (ComBat) was unable to resolve this technical artifact but since it was not associated with main PCs, we believe the effects on the final results are minimal. 
Reverse transcription quantitative polymerase chain reaction (RT-qPCR)
Expression levels of HMGCR (exon 6-7 and exon [13] [14] , DUSP1, RHOB, JUN and FOS in the clinical samples were validated using RT-qPCR. Briefly, one µg of total RNA was reversely transcribed (Quantitect® Reverse Transcription Kit, Qiagen), and cDNA corresponding to five ng of total RNA was used as a template in the qPCR (Quantitect® Probe PCR Kit, Qiagen) with predesigned hydrolysis probe assays (Life Technologies). standard curve was included in each run to verify the reaction efficiency, and no template controls were used. Expression ratios were calculated by the 2 -ΔΔCT formula. All assays used are listed in Supplementary Table S1 . For statistical analysis of related samples, Wilcoxon signed-rank test was applied using SPSS version 19.
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Results
Patients
The average age of all 50 patients at the time of inclusion was 63 years (range: 35-89 years). genes of undefined function located at certain loci, referred to as LOC-genes 323 of the 407 genes remained. Upon further filtration, requiring a fold change of ≥1.49, a total of 67 genes remained; 21 up-regulated and 46 down-regulated (Fig. 1) , which represent the genes used in all subsequent analyses. Dual-specificity phosphatase 1 (DUSP1), also identified as mitogenactivated protein kinase phosphatase-1, a well-known inhibitor of the mitogen-activated protein kinase (MAPK) pathway (18), was significantly up-regulated. Other highly significant up-regulated genes included the Ras homolog family member B (RHOB), growth arrest and DNA-damage-inducible beta (GADD45B), and the regulator of G-protein signaling 1 (RGS1).
In addition, key members of the AP-1 transcription factor complex such as FOS, FOSB, JUN and JUNB were also significantly up-regulated in the post-statin treatment samples. Gene ontology and pathway analyses revealed that GnRH signaling, immune response, PI3K/AKT, MAPK and apoptosis were among the significantly deregulated biological processes and pathways following statin treatment (summarized in Table 1 ).
To further explore the potential functional significance of the altered genes, we OCT, also known as POU class 2 homeobox 1, is a member of the POU domain transcription factor family, and it binds to the octamer motif and interacts with regulatory interleukin and histone genes (22) . 
RT-qPCR validation
relatively similar trends in fold changes as was observed by microarray profiling (Supplementary Fig. S2A ). While DUSP1, RHOB, JUN and FOS were consistently upregulated after treatment in the majority of cases, the expression of HMGCR increased in 12 of 25 cases, while it decreased upon statin treatment in the remaining 13 cases (Supplementary Fig. S2B ). Consistent with the results from microarray SAM analyses, these alterations were not statistically significant (P>0.05). In analyses stratified for treatment effects in terms of any decrease in Ki67, no significant changes in HMGCR were detected in either stratum (data not shown). Similarly, no significant change in HMGCR was observed after stratification by change in protein expression of HMGCR (data not shown).
In vitro statin-treatment-induced gene expression alterations
To test if the observed gene expression changes in the clinical samples were directly associated with statin treatment, total RNA extracted four human breast cancer cell lines was subjected to whole genome transcriptional profiling following 48 hours atorvastatin treatment.
Compared to vehicle (DMSO) treated controls, 48 hours of statin exposure was found to consistently and significantly up-regulate several key genes involved in the cholesterol biosynthesis pathway in all four cell lines (Fig. 4A) . Furthermore, a significant downregulation of genes involved in cell proliferation and cell cycle progression; particularly genes necessary for the G2/M-phase was noted. In addition, a significant up-regulation of many proapoptosis genes was noted in some cell lines. Of note, and consistent with the clinical data, a significant up-regulation of some DUSP genes (DUSP4 and DUSP6) which regulate the MAPK activity, RHOB and the AP-1 transcription factor JUN was seen following statin treatment in a subset of the cell lines. A summary of the significantly altered biological processes and pathways in the cell lines is presented in Fig. 4B . (27) . In line with our results, a study on nonsmall-cell lung cancer cells showed that, overexpression of DUSP-1 was associated with a decrease in cell growth (28) . Evidently, the effects of kinase and phosphatase activity depend on many factors such as time and duration of the activity, as well as tumor type and tumor grade (29) . Improved understanding of the cross talk between substrates within the MAPK pathway and the role of the main down-stream products is necessary. In this study, the GADD45A (33) . Further, GADD45B has been suggested to have a novel function during Fasinduced apoptosis where it acts as an adaptor between p38 and retinoblastoma tumor suppressor (Rb) to enhance p38-mediated phosphorylation of Rb, an important step during Fas-induced apoptosis (34).
Another up-regulated gene in this study, RHOB, is a member of the Ras superfamily of proteins with GTPase activity that are conserved and widely expressed in different tissues. Rho protein expression and/or activity is frequently altered in many types of cancers (35) . Statin induced inhibition of HMGCR, the rate-limiting enzyme in the mevalonate pathway, also causes a decrease of down-stream products such as isopreonids.
The inhibition of isoprenylation results in the inactivation of small GTPase proteins. Unlike its family members RhoA and RhoC, which are often over-expressed in different types of cancers, RhoB has been reported to be down-regulated in human cancers, but in lung and gastric cancer, its expression significantly inhibits proliferation, migration and invasion (35) . 
The mechanism of statin induced anti-proliferative and pro-apoptotic effects in cancer cells is currently not clear. Functional in vitro and in vivo studies have demonstrated mutant p53-dependent up-regulation of genes in the mevalonate pathway in p53 mutant breast cancer cells (36). Furthermore, induction of RhoA-dependent retention of the transcription factor NFkB, leading to transcriptional down-regulation of the anti-apoptotic protein BCL2, and reduced production of AKT1 upon statin treatment has been reported (37) . Induction of apoptosis via activation of the JNK/CHOP/DR5 pro-apoptotic pathway has also been shown (38). Koyuturk et al. showed that statins activate the JNK pathway, leading to apoptosis in breast cancer cell lines, whereas the ERK1/2 and p-38 MAPK pathways were not involved in the anti-cancer activity of simvastatin in that study (39) . In the same study, simvastatin MAPK leads to JNK activation, which activates GADD45B resulting in the induction of apoptosis. On the other hand, RGS1 inhibition on CXCR4 inhibits cell survival.
Gene set enrichment analysis suggested an effect on the immune system, which concurs with previous, reports on statin-induced immunoregulatory effects (40) . The amount of tumor infiltrating lymphocytes (TILs) in tumor tissue has received increasing scientific attention lately in terms of prognosis and treatment prediction (41, 42) . Potential changes in TILs in this study would have been of interest to validate the gene set enrichment results but these analyses were restricted due to limited amount of tumor tissue.
We have previously reported that breast cancers expressing HMGCR in pretreatment samples showed a significant decrease in Ki67 after statin treatment (11) . Both microarray and RT-qPCR analyses showed no significant differences in HMGCR mRNA expression between the pre-and post-treatment samples. However, some sample pairs showed a clear up-regulation whereas others displayed down-regulation of HMGCR mRNA, suggesting that the transcriptional effects of statin treatment observed herein may be dependent upon the regulation of HMGCR in a differential manner. In the statin treated cell lines, however, a significant up-regulation of genes involved in the mevalonate pathway, including HMGCR, was observed. This up-regulation of mevalonate pathway genes corresponds with the previously reported robust homeostatic feed-back response, which is triggered upon the inhibition of HMGCR by statins leading to increased transcriptional activity of the sterol regulatory element-binding proteins (SREBP) transcription factor (1).
The diverse results on mevalonate pathway inhibition seen in the clinical samples compared to the in vitro samples may reflect the interplay between hepatic-driven levels of circulating cholesterol and intracellular cholesterol levels in the tumor in humans (1, 43) .
In this window-of-opportunity phase II trial, we have reported for the first time 
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